UBS Group Analysts Give Fresenius Medical Care AG & Co. KGaA (ETR:FME) a €90.00 Price Target

Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a €90.00 ($104.65) target price by stock analysts at UBS Group in a research note issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 52.34% from the company’s current price.

A number of other equities research analysts have also recently commented on the company. Goldman Sachs Group set a €80.00 ($93.02) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Monday, October 14th. Deutsche Bank set a €100.00 ($116.28) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Credit Suisse Group set a €71.00 ($82.56) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Friday, October 18th. JPMorgan Chase & Co. set a €78.60 ($91.40) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, Nord/LB set a €82.00 ($95.35) price objective on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Thursday, August 1st. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of €78.91 ($91.76).

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at €59.08 ($68.70) on Wednesday. The company has a quick ratio of 0.63, a current ratio of 0.99 and a debt-to-equity ratio of 105.17. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €55.44 ($64.47) and a 12 month high of €76.68 ($89.16). The business has a fifty day simple moving average of €61.16 and a 200 day simple moving average of €66.43. The stock has a market cap of $17.81 billion and a PE ratio of 14.66.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Story: How does the Beige Book influence monetary policy?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.